Clinical Infectious Diseases · 2004 · 128 citations · 2 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyMolecular PharmacologyPharmacovigilanceAntiviral PharmacologyAntiviral TherapyMitochondrial DysfunctionMitochondrial ToxicityMitochondrial ToxicologyViral HepatitisLabelsLactate AcidosisLactic AcidosisNucleoside AnalogsNucleoside Analogue AntiviralsNucleoside Analogue TherapyRibavirin TherapyRibavirin-based Regimens
An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus and chronic hepatitis C virus who were treated with a regimen of ribavirin and didanosine, with or without stavudine, were at increased risk for events associated with mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis. In response, the US product labels for didanosine and ribavirin have been revised to caution clinicians against coadministration of these drugs.
2
Pierrot Harvie, Rabeea F. Omar, Nathalie Dusserre et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 20 citations
Medicine, Immunology, Pharmacology +17